Showing 5861-5870 of 23187 results for "".
Deciphering the Link: Proteinuria and eGFR Dynamics in IgAN and FSGS
https://reachmd.com/programs/clinicians-roundtable/deciphering-the-link-proteinuria-and-egfr-dynamics-in-igan-and-fsgs/37215/High levels of proteinuria are associated with a high risk of kidney failure in the future, both for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). In fact, proteinuria levels can help predict disease progression, outcomes, and even optimal therapeutic approaches. Joining Dr.RISK Cohort Study in Crohn's Disease
https://reachmd.com/programs/crohns-colitis-foundation-perspectives/risk-cohort-study-crohns-disease/9924/Lu Ann Cahn talks w/ Dr. Piccoli about the RISK study that enrolled 1,800 patients & collected a variety of info to learn more about the immune systemEarly Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
https://reachmd.com/programs/project-oncology/early-adulthood-weight-breast-tissue-complexity/48767/Real-World Effectiveness of Liraglutide for Obesity: Multicenter Data From Turkey
https://reachmd.com/programs/clinicians-roundtable/real-world-effectiveness-of-liraglutide-for-obesity-multicenter-data-from-turkey/39655/A large retrospective study across 38 endocrinology clinics in Turkey showed that liraglutide led to meaningful weight loss and metabolic improvements—even at slightly reduced doses. Hear from ReachMD's Ryan Quigley as he reviews recent real-world data on this GLP-1 receptor agonist.mRNA-1283 and the Future of COVID-19 Vaccination Strategies
https://reachmd.com/programs/clinicians-roundtable/mrna-1283-and-the-future-of-covid-19-vaccination-strategies/36421/While the mRNA-1283 COVID-19 vaccine shows comparable safety and immune response to its predecessor, mRNA-1273, its true clinical advantage remains under investigation, and depends in part on its integration into wider vaccination plans. Learn how this evolving vaccine technology may influence futurCAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
https://reachmd.com/programs/project-oncology/car-t-and-bispecifics-in-lbcl-redefining-second-line-therapy-choices/35457/This is a non-certified educational series produced and controlled by ReachMD. The treatment landscape for large B-cell lymphoma (LBCL) is rapidly evolving due to the growing integration of bispecific antibodies into second-line care. While these agents offer promising, targeted options—not only forPatient Perspectives on Subcutaneous vs IV Immunotherapies in Oncology Care
https://reachmd.com/programs/project-oncology/patient-perspectives-on-subcutaneous-vs-iv-immunotherapies-in-oncology-care/36402/How do real-world patients experience subcutaneous versus IV immunotherapies? That’s exactly what a first-of-its-kind U.S. study set out to uncover. Tune in to this Audio Abstract to hear the key findings published in Oncology and Therapy and how they could reshape patient-centered cancer care. RefeOptimizing Schizophrenia Care: Strategies for Managing Side Effects and Treatment Resistance
https://reachmd.com/programs/frontlines-schizophrenia/optimizing-schizophrenia-care-strategies-for-managing-side-effects-and-treatment-resistance/30035/Learn about strategies for managing common therapeutic challenges in schizophrenia.Overcoming Controversies of Irritable Bowel Syndrome
https://reachmd.com/programs/gi-insights/overcoming-controversies-of-irritable-bowel-syndrome/18100/Dive in to learn about solutions to controversies surrounding IBS.GA Management: ODs and MDs Take Stock of the Pipeline
https://reachmd.com/clinical-practice/optometry/ga-management-ods-and-mds-take-stock-of-the-pipeline/28660/Which interventional strategies may lead to positive outcomes for patients with geographic atrophy (GA)? Join Christina Y. Weng, MD, MBA, as she contextualizes select portions of a roundtable moderated by Roger A. Goldberg, MD, MBA. The roundtable included two leading optometrists and two leading re